<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660543</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00002753</org_study_id>
    <secondary_id>NCI-2015-00224</secondary_id>
    <secondary_id>SOL-06062-LX</secondary_id>
    <secondary_id>813</secondary_id>
    <secondary_id>NCI-2015-00204</secondary_id>
    <secondary_id>8097</secondary_id>
    <secondary_id>2753</secondary_id>
    <secondary_id>P30CA069533</secondary_id>
    <nct_id>NCT00660543</nct_id>
  </id_info>
  <brief_title>MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy</brief_title>
  <official_title>Early Assessment of Tumor Response to Therapy Using Ferumoxytol (Code 7228) as an MR Contrast Agent in Patients With Glioblastoma Multiforme (MedDRA Code 10018337)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies how a magnetic resonance imaging (MRI) study with
      ferumoxytol works as a contrasting agent in assessing early response in patients with
      glioblastoma multiforme receiving temozolomide and radiation therapy. Ferumoxytol is a very
      small form of iron particles that are injected into the body and taken up by certain tissues
      which may make these tissues easier to see during imaging. Diagnostic procedures, such as an
      MRI study with ferumoxytol, may help measure a patient's response to earlier treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To characterize glioblastoma multiforme (GBM) tumor vascular properties using ferumoxytol
      (ferumoxytol non-stoichiometric magnetite) and compare to those obtained using gadolinium
      (Gd) based MRI contrast agent.

      II. To characterize vascular changes in GBM tumors associated with standard
      radio/chemotherapy.

      SECONDARY OBJECTIVES:

      I. Cerebral blood flow (CBF), mean transit time (MTT), and time-to-peak (TTP) perfusion
      parameters will be measured for each contrast agent and evaluated in post-hoc analysis.

      II. To obtain qualitative assessment of tumor vascularity using time-of-flight (TOF) magnetic
      resonance (MR) angiography techniques.

      III. To characterize changes in the apparent diffusion coefficient (ADC) of tumor water
      associated with standard radio/chemotherapy in GBM.

      OUTLINE:

      Patients receive gadolinium intravenously (IV) on day 1 and ferumoxytol non-stoichiometric
      magnetite IV on day 2 then undergo dynamic susceptibility contrast enhanced (DSC) MRI, and
      dynamic contrast enhanced (DCE) MRI, diffusion-weighted imaging (DWI) (day 1 only), and TOF
      MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of
      radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks
      after radiation (12 weeks post first dose). Ferumoxytol non-stoichiometric magnetite
      administration continues in the absence of unacceptable toxicity. Patients also receive
      temozolomide and undergo radiation therapy per standard of care.

      After completion of ferumoxytol non-stoichiometric magnetite administration, patients are
      followed up for 4-6 weeks and then periodically until the resolution or stabilization of
      unacceptable toxicities.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Cerebral Blood Volume (CBV)</measure>
    <time_frame>At radiographical progression (between 6 and 12 weeks post first dose of chemoradiation)</time_frame>
    <description>Radiographical progression is determined based on RANO criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Progression on Conventional MR</measure>
    <time_frame>Anytime between baseline and 12 weeks post treatment initiation: average 6 weeks post treatment initiation.</time_frame>
    <description>Tumor progression was assessed by RANO criteria (Wen, 2010).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Adult Brain Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Ferumoxytol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ferumoxytol non-stoichiometric magnetite IV on day 2 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose). Ferumoxytol non-stoichiometric magnetite administration continues in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gadoteridol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gadoteridol Leakage Corrected</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadolinium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Gadoteridol</arm_group_label>
    <arm_group_label>Gadoteridol Leakage Corrected</arm_group_label>
    <other_name>Gd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferumoxytol Non-Stoichiometric Magnetite</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Ferumoxytol</arm_group_label>
    <other_name>Fe3O4</other_name>
    <other_name>Feraheme</other_name>
    <other_name>Ferumoxytol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dynamic Contrast-Enhanced Magnetic Resonance Imaging</intervention_name>
    <description>Undergo DCE MRI</description>
    <arm_group_label>Ferumoxytol</arm_group_label>
    <arm_group_label>Gadoteridol</arm_group_label>
    <arm_group_label>Gadoteridol Leakage Corrected</arm_group_label>
    <other_name>DCE MRI</other_name>
    <other_name>DCE-MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging</intervention_name>
    <description>Undergo DSC MRI</description>
    <arm_group_label>Ferumoxytol</arm_group_label>
    <arm_group_label>Gadoteridol</arm_group_label>
    <arm_group_label>Gadoteridol Leakage Corrected</arm_group_label>
    <other_name>DSC-MRI</other_name>
    <other_name>Dynamic Susceptibility Contrast-Enhanced MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diffusion Weighted Imaging</intervention_name>
    <description>Undergo DWI</description>
    <arm_group_label>Ferumoxytol</arm_group_label>
    <arm_group_label>Gadoteridol</arm_group_label>
    <arm_group_label>Gadoteridol Leakage Corrected</arm_group_label>
    <other_name>Diffusion Weighted MRI</other_name>
    <other_name>DWI</other_name>
    <other_name>DWI MRI</other_name>
    <other_name>DWI-MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI-Based Angiogram</intervention_name>
    <description>Undergo TOF MR angiography</description>
    <arm_group_label>Ferumoxytol</arm_group_label>
    <arm_group_label>Gadoteridol</arm_group_label>
    <arm_group_label>Gadoteridol Leakage Corrected</arm_group_label>
    <other_name>Magnetic Resonance Angiogram</other_name>
    <other_name>MRA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have radiologically and histologically confirmed diagnosis of
             glioblastoma multiforme

          -  Patients must have measurable disease, defined as evident tumors with gadolinium
             enhancement on MRI that is measurable in at least one diameter and visible on both
             axial and sagittal or coronal views

          -  Life expectancy of greater than 6 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 50%)

          -  Patients scheduled for standard therapy (6 weeks radiation therapy (RT) ~ 60 Gy, plus
             temozolomide 75 mg/m^2 during 6 week [w] RT, and followed routine monthly temozolomide
             therapy)

          -  Patients must be on a stable or decreasing dose (up to 8 mg daily) of dexamethasone
             throughout the study

          -  After entry into the study, patients are expected to be followed for at least 1 month
             after the last infusion of ferumoxytol

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation; should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately

          -  Ability to understand and the willingness to sign a written informed consent document;
             all patients, or their legal guardians, must sign a written informed consent and
             Health Insurance Portability and Accountability Act (HIPAA) authorization in
             accordance with institutional guidelines

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy

          -  Patients may not be receiving any other investigational agents

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to ferumoxytol: parenteral iron, parenteral dextran, parenteral
             iron-dextran, or parenteral iron-polysaccharide preparations (Ferumoxytol
             Investigator's Drug Brochure, 2005); patients with significant drug or other allergies
             or autoimmune diseases may be enrolled at the Investigator's discretion

          -  Patients with clinically significant signs of uncal herniation, such as acute
             pupillary enlargement, rapidly developing motor changes (over hours), or rapidly
             decreasing level of consciousness, are not eligible

          -  Patients who require monitored anesthesia for MRI scanning

          -  Patients with history of hemochromatosis or iron overload

          -  Patients with renal insufficiency (glomerular filtration rate (GFR) &lt; 50)

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with ferumoxytol

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Neuwelt</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <results_first_submitted>February 12, 2016</results_first_submitted>
  <results_first_submitted_qc>April 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2016</results_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Edward Neuwelt</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Ferrosoferric Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gadoteridol + Ferumoxytol Contrast Agent</title>
          <description>Subjects all received gadolinium enhanced MR on day 1, ferumoxytol enhanced MR on day 2, and delayed MR imaging on day 3 - this 3 day sequence of imaging was repeated at four time points.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gadoteridol + Ferumoxytol Contrast Agent</title>
          <description>Subjects all received gadolinium enhanced MR on day 1, ferumoxytol enhanced MR on day 2, and delayed MR imaging on day 3 - this 3 day sequence of imaging was repeated at four time points.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="43" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Cerebral Blood Volume (CBV)</title>
        <description>Radiographical progression is determined based on RANO criteria.</description>
        <time_frame>At radiographical progression (between 6 and 12 weeks post first dose of chemoradiation)</time_frame>
        <population>All patients with treated GMB showed apparent tumor progression on conventional MR images.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferumoxytol</title>
            <description>Patients receive gadolinium IV on day 1 and ferumoxytol non-stoichiometric magnetite IV on day 2 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).</description>
          </group>
          <group group_id="O2">
            <title>Gadoteridol</title>
            <description>Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).</description>
          </group>
          <group group_id="O3">
            <title>Gadoteridol Leakage Correction</title>
            <description>Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cerebral Blood Volume (CBV)</title>
          <description>Radiographical progression is determined based on RANO criteria.</description>
          <population>All patients with treated GMB showed apparent tumor progression on conventional MR images.</population>
          <units>mL/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.1"/>
                    <measurement group_id="O2" value="1.38" spread="1.73"/>
                    <measurement group_id="O3" value="2.36" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.003</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Differences between groups were assessed by using the Student paired t test and were graphed by using Bland-Altman plots.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.008</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Differences between groups were assessed by using the Student paired t test and were graphed by using Bland-Altman plots.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Progression on Conventional MR</title>
        <description>Tumor progression was assessed by RANO criteria (Wen, 2010).</description>
        <time_frame>Anytime between baseline and 12 weeks post treatment initiation: average 6 weeks post treatment initiation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tumor Progression on Conventional MR</title>
            <description>Tumor progression was assessed by RANO criteria (Wen, 2010).</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Progression on Conventional MR</title>
          <description>Tumor progression was assessed by RANO criteria (Wen, 2010).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ferumoxytol</title>
          <description>Subjects all received ferumoxytol enhanced MR on day 1, ferumoxytol enhanced MR on day 2, and delayed MR imaging on day 3 - this 3 day sequence of imaging was repeated at four time points</description>
        </group>
        <group group_id="E2">
          <title>Gadoteridol</title>
          <description>Subjects all received gadolinium enhanced MR on day 1, ferumoxytol enhanced MR on day 2, and delayed MR imaging on day 3 - this 3 day sequence of imaging was repeated at four time points</description>
        </group>
        <group group_id="E3">
          <title>Gadoteridol With Leakage Correction</title>
          <description>Subjects all received gadolinium enhanced MR on day 1, ferumoxytol enhanced MR on day 2, and delayed MR imaging on day 3 - this 3 day sequence of imaging was repeated at four time points</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Edward Neuwelt</name_or_title>
      <organization>Oregon Health and Science University</organization>
      <phone>503-494-5626</phone>
      <email>neuwelte@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

